
BRIM — Investor Relations & Filings
BRIM Biotechnology, Inc. specializes in the application of translational science to develop innovative therapies for unmet medical needs. The company utilizes its proprietary Pigment Epithelium-Derived Factor (PEDF) Derived Short Peptide (PDSP) technology platform, which leverages neurotrophic properties to stimulate cell proliferation, wound healing, and tissue regeneration. Its research pipeline primarily targets ophthalmology and degenerative conditions, featuring lead candidates such as BRM421 for dry eye syndrome, BRM424 for neurotrophic keratitis, and BRM521 for osteoarthritis. Operating through an integrated model, the company advances drug candidates to the proof-of-concept stage before pursuing strategic licensing and partnerships for late-stage development. BRIM also incorporates precision medicine and bioinformatics to explore combination therapies and enhance therapeutic outcomes.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 115年年報及股東會資料 — 2026_6885_20260612FE5.pdf | 2026-05-12 | English | |
| 115年年報及股東會資料 — 2026_6885_20260612FE2.pdf | 2026-05-12 | English | |
| 115年年報及股東會資料 — 2026_6885_20260612FE1.pdf | 2026-05-12 | English | |
| 115年年報及股東會資料 — 2026_6885_20260612F02.pdf | 2026-05-12 | Chinese | |
| 115年年報及股東會資料 — 2026_6885_20260612F01.pdf | 2026-05-12 | Chinese | |
| 115年年報及股東會資料 — 2026_6885_20260612F13.pdf | 2026-05-12 | Chinese |
Browse filings by year
1 year| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 45772690 | 115年年報及股東會資料 — 2026_6885_20260612FE5.pdf | 2026-05-12 | English | ||
| 45772689 | 115年年報及股東會資料 — 2026_6885_20260612FE2.pdf | 2026-05-12 | English | ||
| 45772688 | 115年年報及股東會資料 — 2026_6885_20260612FE1.pdf | 2026-05-12 | English | ||
| 45772687 | 115年年報及股東會資料 — 2026_6885_20260612F02.pdf | 2026-05-12 | Chinese | ||
| 45772686 | 115年年報及股東會資料 — 2026_6885_20260612F01.pdf | 2026-05-12 | Chinese | ||
| 45772685 | 115年年報及股東會資料 — 2026_6885_20260612F13.pdf | 2026-05-12 | Chinese | ||
| 45746302 | 115年第1季權益變動表 | 2026-05-11 | Chinese | ||
| 45746232 | 115年第1季現金流量表 | 2026-05-11 | Chinese | ||
| 45741513 | 115年第1季綜合損益表 | 2026-05-11 | Chinese | ||
| 45741321 | 115年第1季資產負債表 | 2026-05-11 | Chinese | ||
| 45544696 | 115年第1季財務報告書 — 202601_6885_AI1.pdf | 2026-05-11 | Chinese | ||
| 33964967 | 115年4月變更登記 | 2026-04-10 | Chinese | ||
| 33964970 | 公司基本資料 | 2026-04-10 | Chinese | ||
| 33902475 | 公告本公司限制員工權利新股收回註銷完成變更登記 | 2026-04-09 | Chinese | ||
| 33893046 | 115年04月僑外投資持股 | 2026-04-09 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
NeoImmuneTech, Inc.
A clinical-stage biopharma developing T cell-focused immuno…
|
950220 | US | Professional, scientific and te… |
|
Neovacs
Biotech firm developing immunotherapies and investing in Bi…
|
ALNEV | FR | Professional, scientific and te… |
|
NervGen Pharma Corp.
Clinical-stage biotech developing treatments to promote ner…
|
NGEN | CA | Professional, scientific and te… |
|
NEUREN PHARMACEUTICALS LIMITED
Develops innovative therapies for rare neurodevelopmental d…
|
NEU | NZ | Professional, scientific and te… |
|
NEURIZON THERAPEUTICS LIMITED
Clinical-stage developer of mTOR modulators for ALS and neu…
|
NUZ | AU | Professional, scientific and te… |
|
NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD
Develops peptide-based therapeutics for neurodegenerative a…
|
NSB | AU | Professional, scientific and te… |
|
NEUROTECH INTERNATIONAL LIMITED
Clinical-stage biopharmaceutical company developing pediatr…
|
NTI | AU | Professional, scientific and te… |
|
NewAmsterdam Pharma Co N.V.
A clinical-stage biopharma developing therapies for metabol…
|
NAMS | NL | Professional, scientific and te… |
|
NEXALIS THERAPEUTICS LTD
Develops small molecule therapies for chronic inflammatory …
|
NX1 | AU | Professional, scientific and te… |
|
NextGen Biomed Ltd.
Develops novel therapeutic delivery systems and pain-free a…
|
NXGN | IL | Professional, scientific and te… |
BRIM via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52650/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52650 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52650 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52650 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52650}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for BRIM (id: 52650)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.